Staging of Early-Stage Lung Cancer without Routine PET in Candidates for Segmentectomy.

Introduction:  We aimed to investigate the accuracy of clinical staging without the routine use of positron emission tomography/computed tomography (PET/CT) in patients with cIA1 and cIA2 non-small-cell lung cancer (NSCLC) scheduled for segmentectomy.

Methods:  A total of 305 consecutive segmentectomies were retrospectively analyzed. Overall survival was calculated using the Kaplan-Meier method. Logistic regression was performed to investigate factors independently associated with pathologic upstaging.

Results:  The Union for International Cancer Control (UICC) upstaging was found in 86 patients (28%). Upstaged patients had longer operative times (146 ± 46 vs. 131 ± 44 minutes, p = 0.009), a higher number of lymph node resection (17 ± 10 vs. 13 ± 8, p = 0.001), and a higher rate of L1 involvement (34 vs. 16%, p < 0.001) than nonupstaged patients. N1 was found in 10 patients (3%) and N2 in 13 patients (4%). Nodal positive patients had longer operation times (154 ± 50 vs. 133 ± 44 minutes, p = 0.031) and higher rates of R1 (9 vs. 1%, p = 0.006) and L1 (39 vs. 20%, p < 0.026) than patients without nodal involvement. The 3- and 5-year overall survival rates for nonupstaged and upstaged patients were 85 and 67% and 67 and 54%, respectively (p = 0.040). In logistic regression, L1 involvement (odds ratio [OR]: 2.394, p = 0.005) and the number of dissected lymph nodes (OR: 1.037, p = 0.016) were independently associated with upstaging. Patients who received PET as part of clinical staging did not have a significantly lower nodal upstaging.

Conclusion:  Selective use of PET/CT based on the results of CT may be a viable option for patients with proven or suspected NSCLC up to 2 cm in size.